Communiqué from the Cyxone extraordinary general meeting December 11, 2017

Today, December 11, 2017, Cyxone AB (publ.) held an extraordinary general meeting. Below is an overview of the motions decided upon. All motions were taken with the necessary majority of votes.

Motion regarding revised authorisation for the board to decide on share issues

In line with the board's proposals, the extraordinary general meeting decided that following the expiration of the authorisation granted at the annual general meeting of May 23, 2017, to authorise the board to decide on new share issues on one or more occasion during the period until the next annual general meeting, with or without divergence from shareholders' preferential rights. Share issues shall be able to be conducted with or without stipulation of allowance, offsets or other terms and conditions. The total number of shares that may be issued under this authorisation shall not surpass 7,500,000, which amounts to a total maximum dilution of around 30 per cent. Insofar as the authorisation may be used for share issues that diverge from shareholders' preferential rights, the issue price must reflect market value, (subject to market-based share issue discounts where appropriate). Insofar as cash issues take place due to the acquisition of Rabeximod from OxyPharma AB, the price of issued stock shall, however, be determined in accordance with what is stated in the acquisition agreement. The purpose of the authorisation is to generate working capital, to conduct and finance acquisitions, and to enable issues to industrial partners within a framework of co- operation and alliance building.

December 11, 2017

Cyxone AB (publ)
Kjell G. Stenberg, CEO
Tel: +46 (0)723 816168
Adelgatan 21
211 22 Malmö

This is information that Cyxone AB is required to publish under the EU Market Abuse Directive. The information was provided under the auspices of the above contact person for publication on December 11, 2017 at 14:00 CET.

About Cyxone
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of substances that inhibit key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank, which can be reached on +46 (0) 8 46 38 000.

About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8


Documents & Links